Recruiting studies: Severe Sickle Cell Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966 FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169 Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Phase 1/Phase 2 · 6 location(s) · Kamau Therapeutics · NCT04819841 Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Phase 1/Phase 2 · 4 location(s) · Washington University School of Medicine · NCT03128996 Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cell
Phase 1/Phase 2 · 2 location(s) · Mark Walters, MD · NCT04774536 HPC Offered for PRESERVE Expansion
Phase N/A · 4 location(s) · Ossium Health, Inc. · NCT07145411 Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05213572 Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling
Phase 2 · 1 location(s) · University of Calgary · NCT03214354 CS-206 in Patients With Sickle Cell Disease
EARLY_Phase 1 · 1 location(s) · CorrectSequence Therapeutics Co., Ltd · NCT06565026 Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Phase N/A · 1 location(s) · Paul Szabolcs · NCT04528355 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338 Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de la Guadeloupe · NCT07000747 RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
Phase 3 · 1 location(s) · King's College Hospital NHS Trust · NCT05392894 Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an
Phase 3 · 6 location(s) · Vertex Pharmaceuticals Incorporated · NCT05477563 Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Phase 1/Phase 2 · 2 location(s) · Emory University · NCT02447874 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
Phase 1 · 1 location(s) · Columbia University · NCT07015684 Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979 Investigation of the Genetics of Hematologic Diseases
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT02720679

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.